In This Article:
The new patent granted by the USPTO strengthens and expands BioMark's global IP portfolio in liquid biopsy, enhancing cancer management solutions.
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - BioMark Diagnostics Inc., (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce the issuance of U.S. Patent No. 17/895.69 by the U.S. Patent and Trademark Office (USPTO). This patent protects the company's Spermidine/spermine N(1)-acetyltransferase 1 (SAT1) legacy assay platform for assessing tumor velocity and treatment response, particularly in glioblastoma patients (GBM) and triple-negative breast cancer (TNBC) patients with specific genetic mutations.
"We are thrilled to announce the issuance of this new patent, underscoring our commitment to advancing liquid biopsy technology for patients with especially challenging cancers," said Rashid Bux, CEO and President of BioMark. "By expanding our patent estate and initiating new research initiatives, we are positioning BioMark as a leading player in the fight against cancer. The successful outcome of these developments will enhance our role in delivering needed solutions in cancer management, ultimately aiming to save lives and improve the quality of patient care."
Glioblastoma Multiforme (GBM)
-
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor in adults. As a grade IV astrocytoma, GBM is highly invasive and aggressive. Current treatments, including surgical resection, radiation, and chemotherapy, yield a median survival time of 15 months. There is a pressing need to develop novel strategies for treating GBM, quickly assess tumor velocity, and effectively monitor treatment response.
-
GBM is relatively rare, with an incidence of about 3.2 per 100,000 people globally each year, translating to approximately 13,000 new cases annually in the United States alone (National Brain Tumor Society).
-
The Glioblastoma Multiforme Treatment Market size is estimated at USD 2.80 billion in 2024 and is expected to reach USD 4.60 billion by 2029, growing at a CAGR of 8%. *
*Source: https://www.mordorintelligence.com/industry-reports/glioblastoma-multiforme-treatment-market.
Triple-Negative Breast Cancer (TNBC)
-
Approximately 1 in 8 women in Canada and the US will be diagnosed with breast cancer in their lifetime. TNBC, the deadliest breast cancer subtype, accounts for about 15% of all breast cancers. Standard treatment is limited to untargeted chemotherapy, though the recent approval of adjuvant-targeted Olaparib for high-risk HER2-negative breast cancer offers an additional option for patients with germline BRCA mutations.
-
Metastatic TNBC patients have a median survival of 2 years. Early detection and effective treatment response assessment can provide clinicians with critical information for therapy decisions.
-
BioMark plans to launch a preclinical study to evaluate the effectiveness of specific adjuvant treatments in TNBC patients with BRCA mutations using its SSAT1 liquid biopsy. This research aims to generate critical data for future clinical trials and potentially offer clinicians a valuable tool for early treatment response assessment.